USANA Health Sciences (NYSE:USNA) Releases FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.400-2.550 for the period, compared to the consensus estimate of 2.780. The company issued revenue guidance of $850.0 million-$880.0 million, compared to the consensus revenue estimate of $883.5 million.

Analyst Upgrades and Downgrades

Separately, DA Davidson decreased their target price on USANA Health Sciences from $48.00 to $46.00 and set a neutral rating for the company in a research note on Tuesday, May 7th.

USANA Health Sciences Price Performance

Shares of USNA traded down $0.24 during mid-day trading on Tuesday, reaching $45.96. The company had a trading volume of 101,257 shares, compared to its average volume of 79,532. The company’s 50-day moving average is $46.37 and its 200-day moving average is $47.12. USANA Health Sciences has a twelve month low of $41.45 and a twelve month high of $69.60. The company has a market capitalization of $875.54 million, a P/E ratio of 14.39, a P/E/G ratio of 1.39 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, April 30th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.17. The company had revenue of $227.80 million during the quarter, compared to the consensus estimate of $223.27 million. USANA Health Sciences had a return on equity of 12.80% and a net margin of 6.88%. As a group, equities analysts expect that USANA Health Sciences will post 2.78 EPS for the current fiscal year.

Insider Buying and Selling

In other USANA Health Sciences news, major shareholder Myron W. Wentz sold 2,202 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $47.79, for a total value of $105,233.58. Following the completion of the transaction, the insider now directly owns 7,877,841 shares of the company’s stock, valued at $376,482,021.39. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, major shareholder Myron W. Wentz sold 2,202 shares of the company’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $47.79, for a total transaction of $105,233.58. Following the sale, the insider now owns 7,877,841 shares in the company, valued at $376,482,021.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Myron W. Wentz sold 13,496 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $45.03, for a total value of $607,724.88. Following the completion of the sale, the insider now owns 7,864,345 shares in the company, valued at approximately $354,131,455.35. The disclosure for this sale can be found here. Insiders sold a total of 31,591 shares of company stock valued at $1,458,098 over the last three months. Company insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.